A randomized phase III trial of afamelanotide (Scenesse®), an agonistic alpha-melanocyte-stimulating hormone (MSH) analogue in the treatment of protoporphyria-induced phototoxicity.

Lesley Rhodes

A randomized phase III trial of afamelanotide (Scenesse®), an agonistic alpha-melanocyte-stimulating hormone (MSH) analogue in the treatment of protoporphyria-induced phototoxicity.

Research output: Contribution to conference › Other

Original language	English
Publication status	Published - 2011
Event	British Association of Dermatologists Porphyrins & Porphyrias - Cardiff, UK Duration: 10 Apr 2011 → 14 Apr 2011

Conference

Conference	British Association of Dermatologists Porphyrins & Porphyrias
City	Cardiff, UK
Period	10/04/11 → 14/04/11

Cite this

@conference{7adc6fbcd3cf4e8e85960332e7530438,

title = "A randomized phase III trial of afamelanotide (Scenesse{\textregistered}), an agonistic alpha-melanocyte-stimulating hormone (MSH) analogue in the treatment of protoporphyria-induced phototoxicity.",

author = "Lesley Rhodes",

year = "2011",

language = "English",

note = "British Association of Dermatologists Porphyrins & Porphyrias ; Conference date: 10-04-2011 Through 14-04-2011",

}